Recently, 8 analysts have shared their insights on Gilead Sciences, offering a range of perspectives from bullish to bearish. These ratings provide a glimpse into the evolving sentiments towards the company over the past 30 days.
Analysts have established 12-month price targets for Gilead Sciences, with an average target of $79.5, a high estimate of $105.00, and a low estimate of $69.00. The current average reflects a 5.03% decline from the previous average price target.
Analyst Actions and Ratings
Here is a breakdown of recent analyst actions, ratings, and adjustments to price targets:
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $74.00 | $74.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $76.00 | $80.00 |
| Tyler Van Buren | TD Cowen | Lowers | Buy | $85.00 | $90.00 |
| Matthew Harrison | Morgan Stanley | Lowers | Equal-Weight | $78.00 | $80.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $74.00 | $76.00 |
| Morten Herholdt | HSBC | Announces | Hold | $69.00 | – |
| Hartaj Singh | Oppenheimer | Maintains | Outperform | $105.00 | $105.00 |
| Colin Bristow | UBS | Lowers | Neutral | $75.00 | $81.00 |
Key Insights
Analysts’ actions reflect responses to changing market dynamics and company performance. Their ratings, from ‘Outperform’ to ‘Underperform’, indicate expectations for Gilead Sciences’ relative performance. Price targets serve as estimates of the stock’s future value, offering investors valuable insights into the company’s potential.
